What is claimed is:

1. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and an isolated polypeptide comprising a paralogue of EBA-175 polypeptide sequence.

2. The pharmaceutical composition of Claim 1, wherein the paralogue of EBA-175 polypeptide sequence is encoded by the sequence of SEQ ID NO:1.

3. The pharmaceutical composition of Claim 1, further comprising an isolated sialic acid binding protein (SABP) binding domain polypeptide in an amount sufficient to induce a protective immune response to *Plasmodium falciparum* merozoites in a mammal.

4. An isolated polypeptide comprising a paralogue of EBA-175 polypeptide sequence.

5. The isolated polypeptide of Claim 4, wherein the paralogue of EBA-175 polypeptide sequence is encoded by the sequence of SEQ ID NO:1.

6. An isolated nucleic acid sequence comprising a paralogue of EBA-175 nucleic acid sequence.

7. The isolated nucleic acid sequence of Claim 6, wherein the paralogue of EBA-175 nucleic acid sequence comprises the sequence of SEQ ID NO:1.

8. A vector comprising a paralogue of EBA-175 nucleic acid sequence.

9. The vector of Claim 8, wherein the paralogue of EBA-175 nucleic acid sequence comprises the sequence of SEQ ID NO:1.

10. A recombinant host cell comprising a paralogue of EBA-175 nucleic acid sequence.

11. The recombinant host cell of Claim 10, wherein the paralogue of EBA-175 nucleic acid sequence comprises the sequence of SEQ ID NO:1.

12. A recombinant host cell comprising the vector of claim 8.

13. A method for an immune response to *Plasmodium falciparum* merozoites in a patient, the method comprising administration to the patient of an immunologically effective amount of a pharmaceutical composition comprising a pharmaceutically acceptable carrier and an isolated polypeptide comprising a paralogue of EBA-175 polypeptide sequence.

14. The method of Claim 13, wherein the paralogue of EBA-175 polypeptide sequence is encoded by the sequence of SEQ ID NO:1.

15. The method of claim 14, further comprising administration to the patient of an immunologically effective amount of an isolated SABP binding domain polypeptide.

16. A recombinant method for making a paralogue of EBA-175 polypeptide, comprising:

expressing the vector of claim 8 in a host cell; and

isolating the paralogue of EBA-175 polypeptide from said host cell.

17. An isolated antibody, wherein the antibody binds a 5' cysteine rich region of an EBA-175 protein paralogue from a *Plasmodium* species.

18. The isolated antibody of Claim 17, wherein the 5' cysteine rich region is a region II.

19. The isolated antibody of Claim 18, wherein the 5' cysteine rich region is a region II/F2.

20. The isolated antibody of Claim 17, wherein the antibody inhibits binding of an EBA-175 protein to a red blood cell.